The substitution of residues glutamic acid 32 and arginine 33 in CD300f to alanine did not affect the capability of CD300f to form complexes, although in the case of the mutated R33Q form found in the MS patient, it seems that it could affect the stability of the protein (Fig. 6C). Here, CD300LF is linked to myeloid sarcoma.